12th January 2022 – (Hong Kong) The Advisory Panel on COVID-19 Vaccines said today (12th) that the Hong Kong government has not yet received applications for the dose package (ie 10 micrograms per dose) of children aged 5 to 11 years, but after review, it is recommended to allow the vaccination of children aged 5 to 11 years by using one-third of the dose of the Comirnaty vaccine for adults.
It is recommended for “off-label use”, and the vaccination plan will be implemented with reference to the recommendations of the relevant scientific committee. In view of the current and expected development of the COVID-19 epidemic, the Panel recommended that the Government should submit the relevant information to the Joint Scientific Committee under the Centre for Health Protection of the Department of Health to consider the necessity and method to vaccinate children aged 5 to 11 years with the adult Comirnaty vaccine.
A government spokesman said that the government will continue to follow up with Fosun Pharma to expand the applicable age of Comirnaty vaccine to cover children aged 5 to 11. In addition, the Panel has also reviewed all the latest clinical and safety data related to the Comirnaty vaccine and CoronaVac vaccine, and believes that no new important safety issues have been found, but continuous monitoring is still required. The quality of both imported vaccines has also passed certification and appropriate quality control tests. The Panel still believes that the benefits of both vaccines outweigh the risks, and there is no need to recommend changes to the use of the two vaccines.